Project Grant R01CA303867
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $644K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $596,501 to The University of Texas Southwestern Medical Center under the Cancer Biology Research program (CFDA 93.396) to investigate molecular mechanisms of translocation renal cell carcinoma (TRCC) using a novel mouse model. The award, effective June 20, 2026, through May 31, 2031, supports fundamental research aimed at understanding how chromosomal translocations of microphtalmia...
- Federal Grant Award Summary The National Cancer Institute awarded a $639,295 Project Grant to the Research Institute at Nationwide Children's Hospital on May 8, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393). This award supports a five-year research initiative extending through April 30, 2031, focused on elucidating the molecular mechanisms governing fusion oncoproteins derived from FET (Fused in Ewing sarcoma, Ewsr1, Taf15) family members fused to ETS transcription...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a $399,129 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on July 15, 2025, with a completion date of June 30, 2027. This award supports research to develop and evaluate improved cancer treatment methods through laboratory and clinical investigation. Specifically, the research leverages a DDX3 inhibitor called RK-33 to alter the metabolic tumor environment in...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $483,395 Project Grant under the Cancer Treatment Research program (CFDA 93.395) beginning September 1, 2025, and concluding August 31, 2027. This research initiative focuses on investigating P300 and CBP (Cyclic AMP-Response Element Binding Protein) as novel therapeutic targets in renal cell carcinoma (RCC), specifically clear cell RCC (ccRCC). The project will examine the therapeutic potential...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a Project Grant of $644,632 under the Cancer Treatment Research program (CFDA 93.395) effective May 1, 2026 through April 30, 2031. The research project focuses on developing novel antibody-drug conjugates (ADCs) targeting gamma-delta T-cell cancers, which affect approximately 1,000 patients annually in the United States. The primary objective is to establish a mechanistic link between genomic...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Johns Hopkins University a $144,193 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) effective September 4, 2025 through August 31, 2030. This award provides protected salary support for Dr. Preethi Korangath to serve as a Laboratory Research Specialist in Dr. Robert Ivkov's laboratory, where she will facilitate the completion of Research Project Grants (R01) by leveraging her expertise...
- Grant Award Summary The Johns Hopkins University received a $155,479 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective June 1, 2026 through May 31, 2028. The award supports the development and preclinical validation of an anti-CCRL2 (C-C motif receptor-like 2) antibody-drug conjugate (ADC) targeting high-risk myelodysplastic syndrome (MDS) and MDS-related acute myeloid leukemia (AML) patients with TP53 mutations or deletions. The...
- Federal Grant Award Summary The National Cancer Institute awarded Johns Hopkins University a $591,419 project grant under the Cancer Treatment Research program (CFDA 93.395) effective May 1, 2026 through April 30, 2031. The award supports the development of low molecular weight theranostics targeting multiple myeloma, a disease characterized by malignant plasma cell expansion in the bone marrow. The research addresses critical gaps in treating therapy-resistant myeloma by developing a...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The National Cancer Institute awarded The Johns Hopkins University a Project Grant totaling $100,228 under the Cancer Research Manpower program (CFDA 93.398) for the project "Investigating the Molecular Mechanisms of MYC-Driven Transcriptional Reprogramming of the Tumor Microenvironment in Prostate Cancer," effective December 1, 2026, through May 31, 2029. This award supports biomedical research training and investigator-initiated research designed to...